<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03549468</url>
  </required_header>
  <id_info>
    <org_study_id>8672</org_study_id>
    <nct_id>NCT03549468</nct_id>
  </id_info>
  <brief_title>The Effect of Low LEVel TrAgus STimulation on the Electrophysiological Substrate of Patients With Ischemic CardioMyopathy Substrate of Subjects With Ischemic CardioMyopathy</brief_title>
  <acronym>ELEVATE-ICM</acronym>
  <official_title>The Effect of Low LEVel TrAgus STimulation on the Electrophysiological Substrate of Patients With Ischemic CardioMyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with ischemic cardiomyopathy (left ventricular ejection fraction &lt;35%) and heart
      failure who already have an implantable device with an atrial lead (dual chamber
      defibrillator or biventricular defibrillator) will undergo sequentially 1. Sham low level
      tragus stimulation (LLTS) (5min), 2. Active LLTS at 5Hz (15min) and 20Hz (15min) and 3.
      Active LLTS group with atrial pacing at 100bpm at 5Hz (15min) and 20Hz (15min). The latter is
      required to examine the effect of LLTS on RA independent of heart rate. Repolarization
      alternans will be measured by analyzing a regular 12-lead ECG using a custom-made software.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Due to COVID-19
  </why_stopped>
  <start_date type="Actual">May 25, 2018</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Repolarization alternans, an ECG measure for susceptibility to VT/VF</measure>
    <time_frame>during acute stimulation procedure</time_frame>
    <description>Repolarization alternans will be measured by analyzing a regular 12-lead ECG using a custom-made software</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Ischemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>low level tragus stimulation (LLTS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with ischemic cardiomyopathy (left ventricular ejection fraction &lt;35%) and heart failure who already have an implantable device with an atrial lead (dual chamber defibrillator or biventricular defibrillator) will undergo sequentially 1. Sham LLTS (5min), 2. Active LLTS at 5Hz (15min) and 20Hz (15min) and 3. Active LLTS group with atrial pacing at 100bpm at 5Hz (15min) and 20Hz (15min).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Low level tragus stimulation</intervention_name>
    <description>All patients will undergo sequentially: sham stimulation; LLTS (5Hz), LLTS (20Hz). The sequence will be repeated during atrial pacing at 100bpm</description>
    <arm_group_label>low level tragus stimulation (LLTS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ischemic cardiomyopathy (LVEF &lt;35%) and heart failure

          2. Implantable device with an atrial lead (dual chamber ICD or CRT-D)

          3. Sinus rhythm at the time of the study

        Exclusion Criteria:

          1. Recent (&lt;6 months) stroke or myocardial infarction

          2. Persistent atrial fibrillation

          3. Recurrent vaso-vagal syncopal episodes

          4. Unilateral or bilateral vagotomy

          5. Pregnancy or breast feeding

          6. Uncontrolled diabetes or hypertension

          7. Sick sinus syndrome and 2nd or 3rd degree AV block (without a pacemaker)

          8. Bifascicular block or prolonged first degree block

          9. Hypotension due to autonomic dysfunction

         10. Inability or unwillingness to understand and/or sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>June 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2018</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ischemic cardiomyopathy; neuromodulation; repolarization alternans</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

